亚太地区心血管代谢疾病市场预测至 2028 年 - COVID-19 影响和按类型（心血管疾病 (CVD)、2 型糖尿病、高血压和肥胖）、治疗（ACE 抑制剂、利尿剂、格华止等）、剂量（片剂和注射剂）、给药途径（口服和静脉注射）、最终用户（医院、诊所和家庭护理机构）和分销渠道（医院药房、零售药房和在线药房）
No. of Pages: 185 | Report Code: TIPRE00026135 | Category: Life Sciences
No. of Pages: 185 | Report Code: TIPRE00026135 | Category: Life Sciences
市场介绍
心脏代谢疾病的特点是一组异常和症状，这些异常和症状会引起个人患心血管疾病的风险。高血压、肥胖、胰岛素抵抗、血脂异常、胆固醇水平 (LDL) 不良和葡萄糖耐量是其中一些症状。患有心脏代谢综合征的人容易患上其他几种危及生命的疾病，例如 2 型糖尿病、中风、冠状动脉疾病 (CAD)、心血管疾病 (CVD) 等。
此外，心脏代谢疾病的日益流行预计将推动预测期内的市场增长。然而，中低收入国家 (LMIC) 对心血管疾病的诊断不足限制了亚太地区心脏代谢疾病市场的增长。
供应链中断和对心血管代谢疾病的巨大需求COVID-19 的有效治疗方法使亚太地区的医疗保健研究行业处于至关重要的境地。已采取禁止性措施来控制这一流行病的蔓延。 COVID-19 大流行广泛影响了亚太地区的经济体。印度（31,769,132）、日本（956,407）、中国（93,289）、韩国（203,926）等国家受到疫情的不利影响。社会经济受到严重影响，负通胀、国内生产总值上升，地区失业率激增。近年来，日本高血压和肥胖症患者不断增加。这些患者罹患 COVID-19 重症的风险极高，因此需要仔细观察和强化治疗。与高血压相比，肥胖的定义在不同的研究/国家中并不一致，这需要考虑。但值得注意的是，CCB针对COVID-19的治疗机制仍有待进一步研究和随机对照临床试验。
市场概况及动态
亚太地区心脏代谢疾病市场预计将从2021年的210.913亿美元增至2028年的289.532亿美元；预计 2021 年至 2028 年复合年增长率为 4.6%。心脏代谢疾病 (CMD) 是全球主要死亡原因之一。这些疾病主要是由不健康的生活方式、缺乏运动、吸烟和不健康的饮食引起的。 CMD 包括心血管疾病 (CVD)、糖尿病和慢性肾功能衰竭。大多数心血管疾病可以通过解决行为危险因素来预防，例如烟草摄入、不健康的饮食选择、肥胖、缺乏身体活动和饮酒。糖尿病是危及生命的慢性疾病之一，尚无功能性治愈方法。它会导致各种并发症并增加过早死亡的总体风险。心脏病、中风、肾衰竭、截肢、视力丧失和神经损伤是与糖尿病相关的主要并发症。由于吸烟、缺乏运动、饮酒和不健康的饮食习惯的增加，患有一种或多种 CMD 的人数有所增加。肥胖症患病率的增加也导致了患有 CMD 的患者群体的增加。随着 CMD 患病率的迅速上升，对适当的心脏代谢疾病治疗的需求猛增，从而导致亚太地区心脏代谢疾病市场的巨大增长。
< u>主要细分市场
从类型来看，心血管疾病细分市场在2020年亚太心脏代谢疾病市场中占据最大份额就治疗而言，ACE抑制剂细分市场占据2020年亚太心脏代谢疾病市场最大份额；就剂量而言，片剂细分市场占据2020年亚太心脏代谢疾病市场最大份额。从给药途径来看，口服细分市场在 2020 年亚太心脏代谢疾病市场中占据最大份额。从最终用户来看，医院细分市场在 2020 年亚太心脏代谢疾病市场中占据最大份额。从分销渠道来看，医院药房细分市场2020年市场份额最大。
主要来源及上市公司
主要来源及上市公司
准备本亚太地区心脏代谢疾病市场报告时提到的一些主要一手和二手来源是公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括礼来公司、拜耳公司、诺华公司、勃林格殷格翰国际有限公司、诺和诺德公司、阿斯利康、Cardax Inc.和Kowa Company, Ltd.
购买报告的理由
亚太地区心脏代谢疾病市场细分
按
类型
治疗
按剂量
按给药途径
最终用户
按分销渠道
按国家/地区
提及的公司
Strategic insights for Asia Pacific Cardiometabolic Diseases involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 21,091.3 Million |
| Market Size by 2028 | US$ 28,953.2 Million |
| Global CAGR (2021 - 2028) | 4.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Cardiometabolic Diseases refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Cardiometabolic Diseases Market is valued at US$ 21,091.3 Million in 2021, it is projected to reach US$ 28,953.2 Million by 2028.
As per our report Asia Pacific Cardiometabolic Diseases Market, the market size is valued at US$ 21,091.3 Million in 2021, projecting it to reach US$ 28,953.2 Million by 2028. This translates to a CAGR of approximately 4.6% during the forecast period.
The Asia Pacific Cardiometabolic Diseases Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Cardiometabolic Diseases Market report:
The Asia Pacific Cardiometabolic Diseases Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Cardiometabolic Diseases Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Cardiometabolic Diseases Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Cardiometabolic Diseases Market
